CRP and rheumatoid arthritis: In the multinational, large-scale, randomized OPTIMA trial, in patients with early RA (duration <1 year) who achieved LDA (28-joint Disease Activity Score based on C-reactive protein [DAS28-CRP] <3.2) by week 26 of treatment with adalimumab (ADA) in combination with MTX (ADA + MTX), the outcomes at week 78 in patients who discontinued ADA at week 26 were similar to those in patients who continued to receive ADA [11].